TissueGene Initiates Phase I Clinical Trial With TG-C

Main Category: Bones / Orthopedics
Also Included In: Arthritis / Rheumatology;  Clinical Trials / Drug Trials
Article Date: 25 Jul 2006 - 0:00 PDT

email icon email to a friend   printer icon printer friendly   write icon opinions  

Current Article Ratings:

Patient / Public:4 stars

4 (1 votes)

Healthcare Prof:4 stars

4 (1 votes)


TissueGene, Inc., a privately- held biopharmaceutical company advancing a pipeline of promising regenerative medicine therapeutics, announced today the acceptance of the Company's Investigational New Drug application (IND), and for the initiation of its Phase I clinical trial evaluating a single dose of TG-C for the treatment of degenerative joint diseases. This clinical trial is designed to assess the safety of TG-C in patients who have opted for total knee arthroplasty.

TissueGene has developed TG-C to regenerate cartilage in patients suffering from degenerative arthritis and more specifically for indications such as osteoarthritis of the knee. As an alternative to other methods of cartilage repair, TG-C will involve minimally invasive injections versus a surgical approach. Other techniques currently involve multiple and often invasive surgical procedures and have mixed results.

"We are pleased with the approval to start our Phase I program with TG-C and feel that our drug candidate has the potential to be not first-in-class, but also best-in-class," stated Dr. K.H. Lee, President, founder and Chief Executive Officer of TissueGene.

About TissueGene:

TissueGene, Inc. is a privately-held biopharmaceutical company developing a pipeline of promising regenerative medicine therapeutics in the field of cell-mediated therapy, and has several related products in development for the treatment of degenerative diseases. TissueGene is focused on harnessing the power of well known, safe and effective growth factors combined with the dynamic regenerative capacity of mammalian cells to develop state of the art therapeutics.

For additional information on the company please visit http://www.tissuegene.com.

TissueGene, Inc.
http://www.tissuegene.com

Article adapted by Medical News Today from original press release.
Visit our bones / orthopedics section for the latest news on this subject.
There are no references listed for this article.
Please use one of the following formats to cite this article in your essay, paper or report:

MLA
Christopher Backing. "TissueGene Initiates Phase I Clinical Trial With TG-C." Medical News Today. MediLexicon, Intl., 25 Jul. 2006. Web.
15 Feb. 2012. <http://www.medicalnewstoday.com/releases/47954.php>

APA
Christopher Backing. (2006, July 25). "TissueGene Initiates Phase I Clinical Trial With TG-C." Medical News Today. Retrieved from
http://www.medicalnewstoday.com/releases/47954.php.

Please note: If no author information is provided, the source is cited instead.


Bones / Orthopedics

Most Popular Articles



Follow Our Bones News On Twitter

Follow Us On Twitter
Get the latest news for this category delivered straight to your Twitter account. Simply visit our Bones / Orthopedics Twitter account and select the 'follow' option.



View list of all 'What Is...' articles »